Hic est a album de latest anticancer medicinae in foro.
I) Epacadostat
Epacadostat is undoubtedly a bright star in the IDO field. The results of clinical trials show that the combination of IDO inhibitors and programmed death receptor 1 (PD-1) monoclonal antibody has some advantages over PD-1 alone. anti. Incyte has reached a cooperation agreement with the two giants of PD-1 monoclonal antibody Merck and BMS, and also extensively explored the combined function of Epacadostat and other immune checkpoint inhibitors. The indications also cover multiple cancer categories, but Incyte seems Not content with this, their every move has attracted much attention. Incyte purchased the global development and commercial rights of all indications of Macrogenis’ PD-1 monoclonal antibody drug MGA012 in October to further strengthen its PD-1 pipeline. It is believed that the combination of MGA012 and Epacadostat will soon begin.
II) T-Rova
Rova T-antibody est medicamento, quod peltas DLL3 cancer cells in aequoreus dapibus. Secundo usus est in treatment of-line combined parva cellula pulmonis cancer et adhuc experimentis probata. AbbVie credit quod combined per Opdivo Rova-T + Yervoy Opdivo et faciam illud in cellula parva victor in pulmone cancer, sed magis orci iudiciis et probare opus fuerit in victoria sua.
III) DIX Arn,
Apalutamide (ARN-509) is a new generation of anti-androgen drugs developed for the treatment of prostate cancer. Johnson & Johnson has been quietly advancing the clinical development of apalutamide, and although these data have not been seen, it is also exciting to see it move towards regulatory agencies. With Johnson & Johnson’s strong business development team, this variety is expected to become a blockbuster drug.
IV) Pertuzumab
As early as June 2012, Pertuzumab was approved by the FDA. It was used in combination with trastuzumab and docetaxel for metastatic breast cancer without anti-HER2 + therapy or chemotherapy. In September 2013, Pertuzumab was further approved by the FDA. It was used in combination with trastuzumab and chemotherapy for neoadjuvant treatment of HER2 + breast cancer. On December 20, 2017, the FDA approved the combination of Pertuzumab with Trastuzumab and chemotherapy for adjuvant treatment of patients with early-stage HER2 + breast cancer with a higher risk of recurrence. At the same time, the FDA changed Pertuzumab’s previous adjuvant therapy for HER2 + breast cancer from accelerated approval to full approval.
V) Opdivo
I-PD late usus est unum ex maxime Opdivo MABS orci in usu, et sunt approbata per FDA in novem indiciis. Opdivo scriptor enumerationem application est secunda-line curatio est non-parva cellula pulmonis cancer in Sina in Sabino agro accitum, CDE bifariam in November II, MMXVII et quod includitur in priori recensionem in CDE bifariam in December XVIII ex eo quod est "significans quae ad usus medicinales curationes ".
VI) Thiopenfigrastin Iniectio
Thiofeigrastin iniectio, 19k (HHPG-19k, polyethylene glycol recombinant granulocyte precursor humanis infusum), adhiberi potest pro neutropenia amet tumore consociata cum chemotherapy in aegris. 19k enumerationem application submisit (CXSS1300007) ut mane ut Martii IV, 4. Quia in foro, quod erat primum, quod est captus per se orci examen-XXII on July, 2013 De May XVIII, MMXVI, indicium edita Hengrui 22k quicquid sexus est recedere ab application, quod pertinet ad investigationem perficiendam esse asseruit et progressus application notitia, et complere atque, ut primum fieri potest. Die Aprilis XXIV, MMXVII, Hengrui applicantur ad re-2015k quicquid sexus est sub nomine thiopefilgrastim iniectio medicamento. Apparuit autem iterum in CDE eadem ratio est de 'obvious commoda curatio existentium ornaret atque excoleret major projects comparari ". Factum est autem cogitavit includi in recensionem prioritate list. Licet illud esset ultima recensionem non includitur in in review est technica perficitur in October XIII, MMXVII et exspectat verificationem on-site. Si felix est, expectat impetro in 18Q2016 CFDA approbatione.
VII) Anlotinib
Anlotinib is a multi-target tyrosine kinase inhibitor, which can effectively inhibit VEGFR, PDGFR, FGFR, c-Kit and other kinases. It has anti-tumor angiogenesis and inhibits tumor growth. It has obtained major national new drugs Special funding for creation. Anlotinib’s application for the treatment of non-small cell lung cancer was accepted by the CDE on March 16, 2017, and it took a special approval channel. On April 27, 2017, it had “significant treatment advantages compared with existing treatments”. The “major project” reason was included in the priority review by CDE. At present, the technical review of the pharmacology and toxicology and clinical parts has been completed, and the pharmacy part is queued for review. After that, it will enter the on-site inspection and issue a three-in-one report.
VIII) Pirlotinib
Pirlotinib is an EGFR / HER2 small molecule inhibitor, developed for the treatment of HER2 + breast cancer, gastric cancer and NSCLC, and has received special funding from the National Key New Drug Development Program. It is a new drug project that Hengrui has high hopes for. Hengrui submitted to CDE a conditional listing application for pirlotinib for breast cancer. The application was accepted by CDE on August 24, 2017, and it took a special approval channel. On September 26, 2017, it had a “significant clinical value, The “major project” reason was included in the priority review by CDE. At present, the technical review of the clinical part has been completed, and the pharmaceutical and pharmacological and toxicological parts are queued for review. It is expected that the CFDA will be approved in 2018Q2.
IX) Fruquintinib
Fruquintinib moleculo est parva, independenter succrevit a precursor VEGFR Hehuang Medicinae. Curatio est, cogitavit ut developed pro colorectal cancer, CARDIACUS cancer et NSCLC. Fruquintinib scriptor application ad colorectal cancer curatio provectus est ex Sabino agro accitum, CDE bifariam a June XXX, MMXVII et quod includitur in priori CDE bifariam a review on September IV, MMXVII propter hoc quod non habet "significant orci valorem; Maior projects ". Hoc tempore, in technica review of pharmacologicae et toxicology est pars perficitur, et queues sunt in velit et orci in pendenti recensionem. Quod expectat ut quicquid sexus est quia probatus est in CFDA 30Q2017.
X) Olapalli
Lynparza est mundi primum ightirab DNA damnum responsio ad secundum precursor (DDR) mechanism. Primum in December MMXIV ad hoc probato FDA-linea quarta et curatio provectus BRCA + ovarian cancer. In July XVII, huius anni, hoc probato FDA quod curatio in patientibus sustentationem pro recta-secundum epithelial ovarian cancer, cancer tubarum uterinarum tubo et relapsus est, qui post prima morte ad platinum-fundatur peritonaei cancer medicinae. Ad date, magis quam 2014 tractata est Lynparza patientibus proficiebat cancer. On October 17th, AstraZeneca / s Mercedon Lynparza summitto est FDA-chemotherapeutic germline BRCA mutationem et HER30,000 metastatic pectus cancer ipsum applicationem (sNDA) accepit FDA quod adeptus erat,
recensionem res absolute, convenit turba expectat significantly ad expand.
XI) Lenvatinib
Matrix potest angustos enzyme targeted Lemvatinib est a multi-regulatory seriem VEGFR1-3 factoribus quos possidet: FGFR1-4, PDGFRα, KIT MEJO in tumore cellulis. Die XIII Februarii, MMXV, hoc est medicamento approbata per FDA ad venalicium ut desiderium amplectitur recensionem et pupillum curatio praefracti ut cancer de summus periculo evolutus glandulae ardens missus IODUM. May XIII, cum probatus per FDA in MMXVI et tractare respectu Afinitor provectus renum anti-cell carcinoma, quod apud priorem VEGF Lorem. Nam signa iecoris cancer, summitto ori fluescentes per applicationem ad ipsum Japan in MMXVII Iunii, in deditionem application sit ipsum, FDA, EMA in MMXVII in July, multa per applicationem ad ipsum CFDA in November III, adeptus est in December 13. Est XVIII, CDE bifariam prius recensionem MMXVII. FDA pupillo datum absolute ad medicamento lenvaltinib hepatocellular carcinoma in facies. XXVII Septembris sNDA est in ori fluescentes non accepit: et facta est consilium approbatione in normam cum X-actione retractationis mensis vexillum, quod imperantur ut probatus ante finem Iulii.
XII) Ceritinib
Ceritinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA on April 29, 2014 for crizotinib for intolerance or disease progression in ALK + non-small cell lung cancer, 2017. May 26 FDA approved first-line treatment for ALK + metastatic non-small cell lung cancer. Novartis’ ceritinib capsule listing application was formally accepted by the CDE on December 11, 2017. It should be included in the priority review later (clinical applications have received priority review). It is expected to be approved by the CFDA in 2018Q4. The above summarizes the latest drugs in the treatment of cancer. The drugs are widely used in lung cancer, gastric cancer, liver cancer, breast cancer, and ovarian cancer.
